血漿タンパク質治療薬市場ータイプ別（凝固因子、免疫グロブリン、アルブミン、C1エステラーゼ阻害剤）、用途別（血友病、原発性免疫不全症、など）、および地域別ー世界予測2022ー2030年
SDKI Inc.は、血漿タンパク質治療薬市場の新レポートを2021年12月15日に発刊しました。この調査には、血漿タンパク質治療薬市場の成長に必要な統計的および分析的アプローチが含まれています。レポートで提供される主要な産業の洞察は、市場の既存のシナリオに関する読者に市場の概要についてのより良いアイデアを提供します。さらに、レポートには、市場の成長に関連する現在および将来の市場動向に関する詳細な議論が含まれています。
レポートのサンプルURL
https://www.sdki.jp/sample-request-115261
レポートのサンプルURL
https://www.sdki.jp/sample-request-115261
The plasma protein therapeutics market is estimated to reach a market value of approximately US $ 53.1 billion by 2030, from a market value of approximately US $ 29.1 billion in 2022, and is expected to grow at a CAGR of 8.98% during the 2022-2030 forecast period. It has been.
Details of the research report
https://www.sdki.jp/press-details/plasma-protein-therapeutics-market/254
Plasma is a protein-rich liquid present in the blood and is immune to coagulation and disease. It plays an important role in serving. They can be used for medical treatments such as autoimmunity, immunodeficiency, neuropathy and bleeding disorders when proteins are separated from plasma. By recovering deficient or lost proteins in plasma, these protein therapies treat definite medical conditions. Plasma protein remedies consisting of infused or injected biological agents are used to treat life-threatening, chronic, and hereditary illnesses.
The increasing emergence of new plasma-derived therapies is a major driver of growth in the plasma protein therapeutics market during the forecast period. In addition, an increase in life-threatening illnesses such as the immune and nervous systems and other illnesses such as rabies, tetanus, hepatitis, A & B and chickenpox are also contributing to the growth of the plasma protein therapeutics market. However, restricted rules and regulations regarding the handling of plasma protein products may curb the growth of the plasma protein therapeutics market during the forecast period.
Plasma protein therapeutics market segment The
plasma protein therapeutics market is by type (coagulation factors, immunoglobulins, albumin, C1 esterase inhibitors) and by application (hemophilia, primary immunodeficiency, idiopathic thrombocytopenia, purpura). Diseases, secondary immunodeficiency, hereditary vascular edema, etc.), and by region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.
Based on type, the plasma protein therapeutics market is divided into coagulation factors, immunoglobulins, albumin, and C1 esterase inhibitors. The albumin segment is expected to gain a significant share during the forecast period. This is driven by the enhanced diagnosis of hypoalbuminemia caused by cirrhosis and hepatitis B. In addition, large demand and utilization in China, the main market for albumin, is expected to boost the growth of the plasma protein therapeutics market. In addition, patients suffering from moderate to severe hemophilia require coagulation factor VIII as prophylactic or on-demand therapy. This has also contributed to the growth of this segment.
Regional Overview of the Plasma Protein Therapeutics Market The
North American region leads the market in terms of market share. This growth is due to increased capital income, increased state-of-the-art technology, and the introduction of innovative therapies. In addition, the presence of a large patient base, an increasing elderly population, and the availability of a well-developed infrastructure to store and maintain high-quality plasma sources will also drive the growth of the plasma protein therapeutics market in the region. It is the main factor that promotes it. Increasing adoption of new therapies and increasing prevalence of the disease are also contributing to the growth of the plasma protein treatment market.
These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, Other Asia Pacific); Latin America (Brazil, Mexico, Argentina, etc.) Latin America); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy) , Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more.
Key Players in the
Plasma Protein Therapeutics Market Key players in the Plasma Protein Therapeutics Market include Takeda Pharmaceutical Company Ltd., China Biologics Products Holdings, Bio Products Laboratory Ltd., ADMA Biologics, Inc., CSL Behring LLC, These include HEMA Biologics LLC, Biotest AG, Grifols SA, Kedrion SPA, Inc. and Baxter International Ltd. The study includes in-depth competitive analysis, corporate profiles, recent developments, and key market strategies for these leading companies in the plasma protein therapeutics market.
Report sample URL
https://www.sdki.jp/sample-request-115261
SDKI Inc. Company profile
SDKI Inc.'s goal is to uncover market scenarios for different countries such as Japan, China, the United States, Canada, the United Kingdom and Germany. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. SDKI has gained trust and a customer base in more than 30 countries and is further focused on expanding its foothold in other pristine economies.
Details of the research report
https://www.sdki.jp/press-details/plasma-protein-therapeutics-market/254
Plasma is a protein-rich liquid present in the blood and is immune to coagulation and disease. It plays an important role in serving. They can be used for medical treatments such as autoimmunity, immunodeficiency, neuropathy and bleeding disorders when proteins are separated from plasma. By recovering deficient or lost proteins in plasma, these protein therapies treat definite medical conditions. Plasma protein remedies consisting of infused or injected biological agents are used to treat life-threatening, chronic, and hereditary illnesses.
The increasing emergence of new plasma-derived therapies is a major driver of growth in the plasma protein therapeutics market during the forecast period. In addition, an increase in life-threatening illnesses such as the immune and nervous systems and other illnesses such as rabies, tetanus, hepatitis, A & B and chickenpox are also contributing to the growth of the plasma protein therapeutics market. However, restricted rules and regulations regarding the handling of plasma protein products may curb the growth of the plasma protein therapeutics market during the forecast period.
Plasma protein therapeutics market segment The
plasma protein therapeutics market is by type (coagulation factors, immunoglobulins, albumin, C1 esterase inhibitors) and by application (hemophilia, primary immunodeficiency, idiopathic thrombocytopenia, purpura). Diseases, secondary immunodeficiency, hereditary vascular edema, etc.), and by region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.
Based on type, the plasma protein therapeutics market is divided into coagulation factors, immunoglobulins, albumin, and C1 esterase inhibitors. The albumin segment is expected to gain a significant share during the forecast period. This is driven by the enhanced diagnosis of hypoalbuminemia caused by cirrhosis and hepatitis B. In addition, large demand and utilization in China, the main market for albumin, is expected to boost the growth of the plasma protein therapeutics market. In addition, patients suffering from moderate to severe hemophilia require coagulation factor VIII as prophylactic or on-demand therapy. This has also contributed to the growth of this segment.
Regional Overview of the Plasma Protein Therapeutics Market The
North American region leads the market in terms of market share. This growth is due to increased capital income, increased state-of-the-art technology, and the introduction of innovative therapies. In addition, the presence of a large patient base, an increasing elderly population, and the availability of a well-developed infrastructure to store and maintain high-quality plasma sources will also drive the growth of the plasma protein therapeutics market in the region. It is the main factor that promotes it. Increasing adoption of new therapies and increasing prevalence of the disease are also contributing to the growth of the plasma protein treatment market.
These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, Other Asia Pacific); Latin America (Brazil, Mexico, Argentina, etc.) Latin America); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy) , Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more.
Key Players in the
Plasma Protein Therapeutics Market Key players in the Plasma Protein Therapeutics Market include Takeda Pharmaceutical Company Ltd., China Biologics Products Holdings, Bio Products Laboratory Ltd., ADMA Biologics, Inc., CSL Behring LLC, These include HEMA Biologics LLC, Biotest AG, Grifols SA, Kedrion SPA, Inc. and Baxter International Ltd. The study includes in-depth competitive analysis, corporate profiles, recent developments, and key market strategies for these leading companies in the plasma protein therapeutics market.
Report sample URL
https://www.sdki.jp/sample-request-115261
SDKI Inc. Company profile
SDKI Inc.'s goal is to uncover market scenarios for different countries such as Japan, China, the United States, Canada, the United Kingdom and Germany. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. SDKI has gained trust and a customer base in more than 30 countries and is further focused on expanding its foothold in other pristine economies.
このプレスリリースには、メディア関係者向けの情報があります
メディアユーザーログイン既に登録済みの方はこちら
メディアユーザー登録を行うと、企業担当者の連絡先や、イベント・記者会見の情報など様々な特記情報を閲覧できます。※内容はプレスリリースにより異なります。
すべての画像
